Inducible nitric oxide synthase: Good or bad?

J 2017

Inducible nitric oxide synthase: Good or bad?

LIND, M., A. HAYES, M. CAPRNDA, D. PETROVIC, L. RODRIGO et. al.

Basic information

Original name

Inducible nitric oxide synthase: Good or bad?

Authors

LIND, M. (36 Australia), A. HAYES (36 Australia), M. CAPRNDA (703 Slovakia), D. PETROVIC (705 Slovenia), L. RODRIGO (724 Spain), Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution) and A. ZULLI (36 Australia)

Edition

BIOMEDICINE & PHARMACOTHERAPY, PARIS, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2017, 0753-3322

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

France

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.457

RIV identification code

RIV/00216224:14110/17:00099908

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.biopha.2017.06.036

UT WoS

000407923000040

Keywords in English

Nitric oxide synthase (NOS); Inducible NOS (iNOS); Endothelial NOS (eNOS); Cyclooxygenase-2 (COX-2); COX-2; Oxidative stress; Cardiovascular diseases

Abstract

V originále

Nitric oxide synthases (NOS) are a family of isoforms responsible for the synthesis of the potent dilator nitric oxide (NO). Expression of inducible NOS (iNOS) occurs in conditions of inflammation, and produces large amounts of NO. In pathological conditions iNOS is regarded as a harmful enzyme and is proposed to be a major contributor to diseases of the cardiovascular system such as atherosclerosis. In this review, we address the notion that iNOS is a detrimental enzyme in disease and discuss its potentially beneficial roles. Additionally, we describe other molecules associated with iNOS in diseases such as atherosclerosis, and current research on therapeutic inhibitors tested to reduced pathology associated with cardiovascular diseases (CVD). (C) 2017 Elsevier Masson SAS. All rights reserved.

Citovat

LIND, M., A. HAYES, M. CAPRNDA, D. PETROVIC, L. RODRIGO, Peter KRUŽLIAK and A. ZULLI. Inducible nitric oxide synthase: Good or bad? BIOMEDICINE & PHARMACOTHERAPY. PARIS: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2017, vol. 93, SEP 2017, p. 370-375. ISSN 0753-3322. Available from: https://dx.doi.org/10.1016/j.biopha.2017.06.036.

@article{1406937,
   author = {Lind, M. and Hayes, A. and Caprnda, M. and Petrovic, D. and Rodrigo, L. and Kružliak, Peter and Zulli, A.},
   article_location = {PARIS},
   article_number = {SEP 2017},
   doi = {http://dx.doi.org/10.1016/j.biopha.2017.06.036},
   keywords = {Nitric oxide synthase (NOS); Inducible NOS (iNOS); Endothelial NOS (eNOS); Cyclooxygenase-2 (COX-2); COX-2; Oxidative stress; Cardiovascular diseases},
   language = {eng},
   issn = {0753-3322},
   journal = {BIOMEDICINE & PHARMACOTHERAPY},
   title = {Inducible nitric oxide synthase: Good or bad?},
   volume = {93},
   year = {2017}
}

TY  - JOUR
ID  - 1406937
AU  - Lind, M. - Hayes, A. - Caprnda, M. - Petrovic, D. - Rodrigo, L. - Kružliak, Peter - Zulli, A.
PY  - 2017
TI  - Inducible nitric oxide synthase: Good or bad?
JF  - BIOMEDICINE & PHARMACOTHERAPY
VL  - 93
IS  - SEP 2017
SP  - 370-375
EP  - 370-375
PB  - ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
SN  - 07533322
KW  - Nitric oxide synthase (NOS)
KW  - Inducible NOS (iNOS)
KW  - Endothelial NOS (eNOS)
KW  - Cyclooxygenase-2 (COX-2)
KW  - COX-2
KW  - Oxidative stress
KW  - Cardiovascular diseases
N2  - Nitric oxide synthases (NOS) are a family of isoforms responsible for the synthesis of the potent dilator nitric oxide (NO). Expression of inducible NOS (iNOS) occurs in conditions of inflammation, and produces large amounts of NO. In pathological conditions iNOS is regarded as a harmful enzyme and is proposed to be a major contributor to diseases of the cardiovascular system such as atherosclerosis. In this review, we address the notion that iNOS is a detrimental enzyme in disease and discuss its potentially beneficial roles. Additionally, we describe other molecules associated with iNOS in diseases such as atherosclerosis, and current research on therapeutic inhibitors tested to reduced pathology associated with cardiovascular diseases (CVD). (C) 2017 Elsevier Masson SAS. All rights reserved.
ER  -

LIND, M., A. HAYES, M. CAPRNDA, D. PETROVIC, L. RODRIGO, Peter KRUŽLIAK and A. ZULLI. Inducible nitric oxide synthase: Good or bad? \textit{BIOMEDICINE \&{}amp; PHARMACOTHERAPY}. PARIS: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2017, vol.~93, SEP 2017, p.~370-375. ISSN~0753-3322. Available from: https://dx.doi.org/10.1016/j.biopha.2017.06.036.

Detailed Information on Publication Record